|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cryptocurrency News Articles
GeneVentiv Obtains $2.5 Million SBIR Grant to Develop Hemophilia Gene Therapy
Apr 24, 2024 at 08:00 pm
GeneVentiv Therapeutics has received a $2.5 million grant to conduct preclinical tests on its one-time infusion gene therapy for hemophilia A and B, with or without clotting factor inhibitors. The therapy, GENV-HEM, will be tested in a large study with a canine model of hemophilia, following promising results in mouse models of both hemophilia types. Funds will also be used to evaluate the gene therapy's distribution in the body and associated toxicology. These studies are expected to support a future investigational new drug application for the therapy.
GeneVentiv Secures $2.5 Million SBIR Grant to Advance One-Time Infusion Gene Therapy for Hemophilia
GeneVentiv Therapeutics, a pioneering biotechnology company, has received a prestigious $2.5 million Small Business Innovation Research (SBIR) grant from the National Heart, Lung, and Blood Institute, a division of the esteemed National Institutes of Health. This grant marks a significant milestone in the development of GeneVentiv's transformative gene therapy, GENV-HEM, for the treatment of hemophilia A and B, both with and without clotting factor inhibitors.
GENV-HEM, a one-time infusion gene therapy, has demonstrated remarkable promise in treating hemophilia in preclinical mouse models. The SBIR grant will enable GeneVentiv to further evaluate the therapy's efficacy and safety in a larger study using a canine model of hemophilia. The canine model offers a more robust representation of human physiology, providing valuable insights into the therapy's performance in a setting closer to that of patients.
The grant will also support critical studies to assess the biodistribution and toxicology of GENV-HEM in the body. These comprehensive investigations are essential for establishing the safety profile of the therapy and for preparing an Investigational New Drug (IND) application, which would allow GENV-HEM to enter human clinical trials.
"This SBIR grant is a resounding endorsement of the transformative potential of GENV-HEM," said Paris Margaritis, Chief Scientific Officer of GeneVentiv. "The findings from our mouse studies have been tremendously encouraging, and this grant will enable us to validate these results in a larger animal model and conduct the rigorous safety assessments required for IND submission."
Hemophilia, a rare genetic disorder characterized by excessive and prolonged bleeding, affects approximately 1 in 5,000 males worldwide. The condition arises from deficiencies or malfunctions of clotting factors, primarily factor VIII (FVIII) in hemophilia A and factor IX (FIX) in hemophilia B.
Current treatment options for hemophilia include factor replacement therapy, which involves administering synthetic or plasma-derived clotting factors. However, this approach can be limited by the development of neutralizing antibodies (inhibitors) that prevent the clotting factors from functioning properly.
GENV-HEM employs a cutting-edge gene therapy approach that aims to overcome these challenges. The therapy utilizes a harmless adeno-associated virus (AAV) as a carrier to deliver a gene encoding activated clotting factor V (FVa). FVa interacts with another clotting protein, factor X (FX), initiating a cascade of events that lead to the formation of blood clots independently of FVIII or FIX.
"GENV-HEM has the potential to revolutionize the treatment of hemophilia by offering a single-infusion, lifetime solution for patients with and without inhibitors," said Damon Race, CEO of GeneVentiv. "This grant from the NIH is a pivotal step towards bringing this life-changing therapy to patients."
In recognition of its significant therapeutic potential, GENV-HEM has been granted orphan drug designation by the U.S. Food and Drug Administration (FDA) for the treatment of hemophilia A and B. GeneVentiv has also forged a strategic collaboration with ReciBioPharm to ensure that GENV-HEM meets the stringent Good Manufacturing Practice (GMP) standards and Good Laboratory Practice (GLP) requirements for manufacturing and testing.
"The combined support of this grant and our manufacturing partnership with ReciBioPharm significantly reduces the financial burden on investors while maximizing resources for the critical IND-enabling studies," added Race. "This grant brings us one step closer to submitting the IND for GENV-HEM, paving the way for human clinical trials and ultimately providing a transformative treatment option for patients with hemophilia."
The SBIR grant from the NIH represents a testament to the groundbreaking nature of GeneVentiv's gene therapy approach for hemophilia. With promising preclinical results, a robust canine study, and comprehensive safety assessments underway, GENV-HEM is poised to make a profound impact on the lives of hemophilia patients worldwide.
Disclaimer:info@kdj.com
The information provided is not trading advice. kdj.com does not assume any responsibility for any investments made based on the information provided in this article. Cryptocurrencies are highly volatile and it is highly recommended that you invest with caution after thorough research!
If you believe that the content used on this website infringes your copyright, please contact us immediately (info@kdj.com) and we will delete it promptly.
-
- Bitcoin Nears 1-Month High as Yen Stagnates With Japanese Markets on Holiday
- Sep 23, 2024 at 06:15 pm
- Bitcoin was the notable mover as it reached for one-month highs on Monday, sustaining its rally after the Federal Reserve's super-sized rate cut last week
-
- Neiro (NEIRO) and $SATO Tokens Skyrocket as the Crypto World Pays Tribute to the Late Kabosu the Shiba Inu
- Sep 23, 2024 at 06:15 pm
- After Kabosu's passing earlier this year, the crypto world responded by creating a wave of new tokens in her memory.
-
- DOGE Price Drops 16% in a Week, Can Memebet Casino (MEMEBET) Token Reverse the Trend?
- Sep 23, 2024 at 06:15 pm
- The DOGS/USD chart analysis on the 4-hour chart shows that the token has been on a sustained downtrend since September 14
-
- Stock Trading Courses & Certifications Online - Free and Paid
- Sep 23, 2024 at 06:15 pm
- Learn stock trading courses online from the best institutes like NSE Academy, Upstox, and Angel One. Get certified in technical analysis, fundamental analysis
-
- Oil Folex Review: Is It a Scam or Legit Trading Platform?
- Sep 23, 2024 at 06:15 pm
- Oil Folex is an automated trading system that uses AI, algorithms, and analytics to assess real-time market conditions and execute orders.
-
- EdgeX Exchange, the Disruptor of the Centralized Derivatives Trading Landscape, Launches on the Mainnet
- Sep 23, 2024 at 06:15 pm
- New York, NY – EdgeX Exchange is a decentralized derivatives trading platform incubated by Amber Group, bringing a novel decentralized trading experience to global users and is recently celebrating its launch on the mainnet.
-
- Crypto Analyst Ali Martinez Says Altcoin Season Is Approaching, Dogecoin (DOGE) Set to Benefit
- Sep 23, 2024 at 06:15 pm
- Martinez tells his 71,900 followers on the social media platform X that Bitcoin dominance – which tracks the market cap of BTC versus the rest of crypto assets – is currently nearing the end of a rising wedge
-
- PEPE Development Team Deposits 10B $PEPE ($81.2K) to Binance
- Sep 23, 2024 at 06:15 pm
- Around 22 hours ago, the PEPE development team deposited 10 billion PEPE (worth $81.2K) to Binance from their wallet 0x310:
-
- Ronin Forge Unveils Its First Batch of Grantees as Sky Mavis Aims to Build a Web3 Gaming Network
- Sep 23, 2024 at 06:15 pm
- Aiming to build a network of web3 game developers and help them produce more crypto games that will onboard gamers and create a community, Sky Mavis